Compatibility of topical therapies for psoriasis: Challenges and innovations

Cutis

Volumn 79, Issue 1 SUPPL. 2, 2007, Pages 5-10

  Lebwohl, Mark G ^a   Corvari, Linda ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b P value Communications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG COMBINATION; DRUG INTERACTION; HUMAN; PHOTOTHERAPY; PSORIASIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; PSORIASIS; ULTRAVIOLET THERAPY;

EID: 33846862451     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Feldman SR, Gelfand JM, Stein Gold L, et al. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007;79(suppl 1[ii]):18-31.
2. Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol. 1998;39(2 pt 3):S67-S73.
3. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997;37:85-92.
4. Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol. 1998;134:57-60.
5. Hecker D, Worsley J, Yueh G, et al. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol. 2000;42:1008-1011.
6. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53(suppl 1):S50-S58.
7. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39(4 pt 1):590-596.
8. Kaidbey K, Kopper SC, Sefton J, et al. A pilot study to determine the effects of tazarotene gel 0.1% on steroid induced epidermal atrophy. Int J Dermatol. 2001;40:468-471.
9. Tazorac [package insert]. Irvine, Calif: Allergan, Inc; 2003.
10. Hecker D, Worsley J, Yueh G, et al. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol. 1999;411927-930.
11. Ashcroft DM, Po AL, Williams HC, et al. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. Br Med J, 2000;320:963-967.
12. Ling MR. Extemporaneous compounding: the end of the road. Dermatol Oin. 1998;16:321-327.
13. Feldman SR, Fleischer AB Jr, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J. Dermatol. 2000;39:41-44.
14. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35:268-269.
15. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol. 1997;37(3 pt 2):S55-S58.
16. Lebwohl M, Yoles A, Lombardi K, et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39:447-450.
17. Traulsen J, Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int J Dermatol. 2004;43:611-617.
18. Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereal 2002;82:131-135.
19. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.
20. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147:316-323.
21. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205:389-393.
22. Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004;209:308-313.
23. Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150:1167-1173.
24. Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week randomised, double-blind safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet) in the treatment of psoriasis vulgaris. Dermatology. 2006;213:319-326.
25. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/ Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154:1155-1160.
26. Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol. 1994;130:79-82.
27. Bourke JF, Iqbal SJ, Hutchinson PE. The effects of UVB plus calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. Gin Exp Dermatol. 1997;22:259-261.
28. Kragballe K. Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. Dermatologica. 1990;181:211-214.
29. Hofmann UB, Eggert AA, Brocker EB, et al. Calcitriol vs dithranol in combination with narrow-band ultraviolet B (311 nm) in psoriasis. Br J Dermatol. 2003;148:779-783.
30. Brands S, Brakman M, Bos JD, et al. No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J Am Acad Dermatol. 1999;41:991-995.
31. Fetil E, Ilknur T, Altiner D, et al. Effects of calcipotriol cream and ointment, clobetasol cream and ointment and tretinoin cream on the erythemogenicity of UVB. J Dermatol. 2005;32:868-874.
32. Lebwohl M, Hecker D, Martinez J, et al. Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol. 1997;37:93-95.
33. De Rie MA, Di Nuzzo S, Brands S, et al. Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema. Br J Dermatol. 2000;142:1160-1165.
34. Dovonex [package insert]. Thornhill, Ontario, Canada: LEO Pharma, Inc; 2006.
35. Lebwohl M, Quijije J, Gilliard J, et al. Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol. 2003;121:594-595.
36. Levitt J, Feldman T, Riss I, et al. Compatibility of desoximetasone and tacrolimus. J Drugs Dermatol. 2003;2:640-642.